The GLP-1RAs group had a lower rate of adverse CVEs, including new-onset heart failure (HR 0.88
Due to the longer half-life of the medication, Ozempic continues to circulate in the body even after treatment stops
Unlike PDE5 inhibitors, PT-141 works through central nervous system pathways rather than peripheral blood vessel dilation
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List
GLP-1s restore the signal that says "I've had enough." Slow Gastric Emptying Food stays in your stomach longer, which: Extends the feeling of fullness after meals Reduces blood sugar spikes Decreases the urge to snack between meals Improve Glucose Metabolism GLP-1s help your pancreas release insulin more effectively in response to meals (glucose-dependent insulin secretion)
Quality of evidence: I-A, Strength of recommendation: 1 Panel level of agreement: In total agreement 96%, in partial agreement 4% Recurrent HE occurs in 4757% patients per year and is related to poor prognosis in patients with cirrhosis, making its control an important goal